875781-15-0

Usage

Uses

Used in Pharmaceutical Industry:
5-Bromo-2-fluoropyridine-3-carboxaldehyde is used as a key intermediate in the synthesis of 2,3-dipyrimidine derivatives, which are known as Raf kinase inhibitors. These inhibitors play a crucial role in the development of targeted therapies for the treatment of various cancers by modulating the Raf/MEK/ERK signaling pathway, which is often dysregulated in cancer cells.
Additionally, 5-Bromo-2-fluoropyridine-3-carboxaldehyde is used in the preparation of factor Xa (FXa) inhibitors. FXa is a serine protease enzyme involved in the coagulation cascade, and its inhibition can help prevent blood clot formation in various thrombotic disorders. The development of FXa inhibitors using 5-Bromo-2-fluoropyridine-3-carboxaldehyde can lead to the creation of novel anticoagulant drugs with improved safety and efficacy profiles.

InChI:InChI=1/C6H3BrFNO/c7-5-1-4(3-10)6(8)9-2-5/h1-3H

Upstream product

• 766-11-0 5-bromo-2-fluoropyridine 
• 2591-86-8 N-Formylpiperidine 
• 109-94-4 formic acid ethyl ester 

Downstream Products

• 1083326-08-2 5-bromo-3-(4,4,5,5-tetramethyl-1,3-dioxolan-2-yl)-2(1H)-pyridinone hydrazone 
• 1111637-73-0 1-(5-bromo-2-fluoropyridin-3-yl)ethanol 
• 875781-17-2 5-bromo-7-azaindazole 
• 1422387-06-1 tert-butyl N-[(1S)-1-[5-(2-amino-4-nitrophenyl)-2-fluoropyridin-3-yl]but-3-en-1-yl]carbamate 
• 1422387-07-2 tert-butyl N-[(1S)-1-(5-{2-amino-4-[(methoxycarbonyl)amino]phenyl}-2-fluoropyridin-3-yl)but-3-en-1-yl]carbamate 
• 1422388-72-4 C₂₀H₂₅FN₄O₂ 
• 1422387-08-3 methyl (4-(5-((1S)-1-((tert-butoxycarbonyl)amino)but-3-en-1-yl)-6-fluoropyridin-3-yl)-3-((2-methylbut-3-enoyl)amino)phenyl)carbamate 
• 1422387-30-1 2-(1-(3-chlorophenyl)-4-(((7S)-9-fluoro-15-((methoxycarbonyl)amino)-3-methyl-2-oxo-2,3,4,5,6,7-hexahydro-1H-8,12-(metheno)-1,10-benzodiazacyclotetradecin-7-yl)carbamoyl)-1H-pyrazol-3-yl)ethyl methanesulfonate 
• 882670-89-5 6-bromopyrido[2,3-d]pyrimidin-2-amine 
• 1111637-74-1 1-(5-bromo-2-fluoropyridin-3-yl)ethanone 

Relevant academic research and scientific papers

PROCESS FOR PREPARING ALKYNYL-CONTAINING COMPOUND AND INTERMEDIATE THEREOF

Disclosed are processes for preparing alkylnyl-containing compounds of Formula (I) as shown below, intermediates and related compounds thereof. Pharmaceutical compositions comprising the compounds and methods of treating cancer thereof are also disclosed.

LPA RECEPTOR ANTAGONISTS AND USES THEREOF

The present disclosure relates generally to compounds that bind to Lysophosphatidic Acid Receptor 1 (LPAR1) and act as antagonists of LPAR1. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of LPAR1, including fibrosis and liver diseases such as non alcoholic steatohepatitis (NASH).

3-(1H-PYRROLO[3,2-C]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF

7-Azaindazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of a 7-azaindazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, fibrotic disorders, bone or cartilage diseases, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.

3-(1H-PYRROLO[2,3-C]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF

7-Azaindazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of a 7-azaindazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, fibrotic disorders, bone or cartilage diseases, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.

3-(1H-INDOL-2-YL)-1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF

7-Azaindazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of a 7-azaindazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, fibrotic disorders, bone or cartilage diseases, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.

3-(1H-PYRROLO[2,3-B]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF

7-Azaindazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of a 7-azaindazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, fibrotic disorders, bone or cartilage diseases, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.

Synthesis of 5-cyano -1H-pyrazolo [3,4-b] pyridine method

The invention discloses a method for synthesis of 5-cyano-1H-pyrazolo[3,4-b]pyridine. The method comprises the following steps of synthesizing LDA, synthesizing an intermediate I, synthesizing an intermediate II, synthesizing a 5-cyano-1H-pyrazolo[3,4-b]pyridine finished product and carrying out follow-up purification treatment. The method utilizes cheap and easily available raw materials, greatly reduces a production cost, has a reasonable raw material ratio, simple and short processes and mild conditions, is safe and reliable, can prepare a target product having high purity and is especially suitable for industrial production.

GPR40 RECEPTOR AGONIST, METHODS OF PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AS AN ACTIVE INGREDIENT

The present invention relates to a novel compound having GPR40 receptor agonist activity that promotes insulin secretion and inhibits blood sugar rise after glucose loading, and is thereby useful for the treatment of diabetes and complications thereof, the preparation method thereof and pharmaceutical composition containing them as an active ingredient.

PYRAZOLE COMPOUNDS

The present invention is directed to compounds of Formula (I) and to pharmaceutically acceptable salts thereof, their synthesis, and their use as Raf inhibitors.

QUINAZOLINE DERIVATIVES AS PI3 KINASE INHIBITORS

Invented is a method of inhibiting the activity/function of P13 kinases using quinazoline derivatives. Also invented is a method of treating one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection and lung injuries by the administration of quinazoline derivatives.